title: Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride.
abstract: The present study addresses the question of a possible linkage between the cystic fibrosis (CF) genetic autosomal recessive disorder and disturbance in neutrophil function. Neutrophil-dominated chronic airway inflammation is present at an early age in children with CF, even in the absence of detectable infection. As evidenced by extracellular superoxide anion release (measured by lucigenin luminescence) or intracellular hydrogen peroxide production (measured by 2',7'-dichlorofluorescein (DCF) fluorescence), no significant difference in the nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase activity of isolated neutrophils was observed in noninfected CF children (homozygotes), their mothers or fathers (CF heterozygotes), and controls. In contrast, both myeloperoxidase (MPO)-dependent oxygenation activity (measured by luminol luminescence) and chloramine release were increased significantly in both CF homozygotes and heterozygotes as compared with controls. In the presence of either amiloride (a sodium channel inhibitor and sodium/proton antiport blocker) or EIPA (5-ethyl-N-isopropyl-amiloride, a specific inhibitor of the antiport), or choline buffer, intracellular MPO activity was decreased significantly in controls and in the CF homozygotes and heterozygotes, thus bringing intracellular MPO-dependent activity in CF subjects back to the level of controls. Extracellular release of MPO, measured by an ELISA to provide an activity-independent assessment of the enzyme, was increased only in CF homozygotes, and was decreased by amiloride and choline buffer, but not by EIPA. We conclude that a modification of intracellular pH and/or ionic concentrations may be related to the altered MPO enzymatic activity observed in CF neutrophils.
authors.affiliation: INSERM Unit 90, The Necker Hospital, Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Witko-Sarsat
authors.forename: R C
authors.initials: RC
authors.lastname: Allen
authors.forename: M
authors.initials: M
authors.lastname: Paulais
authors.forename: A T
authors.initials: AT
authors.lastname: Nguyen
authors.forename: G
authors.initials: G
authors.lastname: Bessou
authors.forename: G
authors.initials: G
authors.lastname: Lenoir
authors.forename: B
authors.initials: B
authors.lastname: Descamps-Latscha
mesh_terms: D000293:Adolescent; D000584:Amiloride / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000201:enzymology*; D009195:Peroxidase / Q000502:physiology*
chemical_list: D000584:Amiloride; D009195:Peroxidase